Abstract
The clinical and immunological evolution of lesions in cutaneous leishmaniasis was assessed after treatment with human recombinant gamma interferon (rIFN-gamma). 3 weeks after rIFN-gamma treatment of lesions due to Leishmania braziliensis guyanensis, 12/13 had become smaller compared with 6/13 control lesions; only 4 treated lesions were free of parasites. 9 of 13 L tropica lesions treated with rIFN-gamma resolved completely within 4-8 weeks of treatment. An acute inflammatory reaction around treated lesions was more common in lesions due to L tropica. There were no other local or systemic adverse reactions. Histological and immunohistochemical studies indicate that local application of rIFN-gamma enhances cell-mediated immune responses and thus promotes healing of cutaneous leishmaniasis.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
MeSH terms
-
Acute Disease
-
Administration, Topical
-
Adolescent
-
Adult
-
Animals
-
Antibodies, Protozoan / analysis
-
Biopsy
-
Brazil
-
Clinical Trials as Topic
-
Female
-
HLA-DR Antigens / analysis
-
Humans
-
Immunity, Cellular
-
Immunoglobulin E / analysis
-
Injections, Subcutaneous
-
Interferon-gamma / administration & dosage*
-
Interferon-gamma / adverse effects
-
Interferon-gamma / therapeutic use
-
Leishmania braziliensis / immunology
-
Leishmaniasis / immunology
-
Leishmaniasis / pathology
-
Leishmaniasis / therapy*
-
Leukocyte Count
-
Male
-
Middle Aged
-
Receptors, Interleukin-2 / analysis
-
Recombinant Proteins
-
Skin / pathology
-
Syria
-
T-Lymphocytes / immunology
-
Time Factors
Substances
-
Antibodies, Protozoan
-
HLA-DR Antigens
-
Receptors, Interleukin-2
-
Recombinant Proteins
-
Immunoglobulin E
-
Interferon-gamma